newsfilter
← Earnings
Earnings Releases·

Alumis — Third Quarter 2026 Earnings Summary

  • Total revenue decreased to $1.9 million from $2.1 million in the prior year period, while net loss narrowed to $94.9 million from $110.8 million, driven by reduced R&D expenses following the completion of pivotal Phase 3 trials.
  • The company maintains a cash position of $431.3 million, sufficient to fund operations through Q4 2027, and remains on track to submit an NDA for envudeucitinib in plaque psoriasis in Q4 2026.
  • Envudeucitinib demonstrated robust efficacy in the ONWARD3 psoriasis program with a 54% PASI 100 response rate at Week 48, whereas the Phase 2b LUMUS trial for SLE missed primary endpoints in the overall population despite positive results in an IFNGS-high subgroup.
  • Strategic milestones include the initiation of a Phase 2 biomarker trial for A-005 in Parkinson's disease in 2027 and the completion of the ACELYRIN merger, which previously impacted prior-year expenses.
Company
ALUMIS INC
Sector
Healthcare
Industry
Biotechnology